Identification and Visualization of CD8+ T Cell Mediated IFN-γ Signaling in Target Cells during an Antiviral Immune Response in the Brain

Mariana Puntel, Robert Barrett, Nicholas S. R. Sanderson, Kurt M. Kroeger, Niyati Bondale, Mia Wibowo, Sean Kennedy, Chunyan Liu, Maria G. Castro, Pedro R. Lowenstein

Abstract

CD8+ T cells infiltrate the brain during an anti-viral immune response. Within the brain CD8+ T cells recognize cells expressing target antigens, become activated, and secrete IFN-γ. There are no methods to recognize individual cells that respond to IFN-γ. Using a model that studies the effects of the systemic anti-adenoviral immune response upon brain cells infected with an adenoviral vector in mice, we describe a method that identifies individual cells that respond to IFN-γ. To identify individual mouse brain cells that respond to IFN-γ we constructed a series of adenoviral vectors that contain a transcriptional response element that is selectively activated by IFN-γ signaling, the gamma-activated site (GAS) promoter element; the GAS element drives expression of a transgene, Cre recombinase (Ad-GAS-Cre). Upon binding of IFN-γ to its receptor, the intracellular signaling cascade activates the GAS promoter, which drives expression of the transgene Cre recombinase. We demonstrate that upon activation of a systemic immune response against adenovirus, CD8+ T cells infiltrate the brain, interact with target cells, and cause an increase in the number of cells expressing Cre recombinase. This method can be used to identify, study, and eventually determine the long term fate of infected brain cells that are specifically targeted by IFN-γ. The significance of this method is that it will allow to characterize the networks in the brain that respond to the specific secretion of IFN-γ by anti-viral CD8+ T cells that infiltrate the brain. This will allow novel insights into the cellular and molecular responses underlying brain immune responses.

Citation: Puntel M, Barrett R, Sanderson NS, Kroeger KM, Bondale N, et al. (2011) Identification and Visualization of CD8+ T Cell Mediated IFN-γ Signaling in Target Cells during an Antiviral Immune Response in the Brain. PLoS ONE 6(8): e23523. doi:10.1371/journal.pone.0023523

Editor: Maciej S. Lesniaik, The University of Chicago, United States of America

Received July 13, 2011; Accepted July 18, 2011; Published August 29, 2011

Copyright: © 2011 Puntel et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: Work in the Board of Governors’ Gene Therapeutics Research Institute was funded by National Institutes of Health/National Institute of Neurological Disorders and Stroke Grant 1R01 NS052465-01. The brain tumor program in the authors’ institute was funded by National Institutes of Health/National Institute of Neurological Disorders and Stroke Grants 1R01-NS 057711 and 1R21-NS054143 (to M.G.C.) and National Institutes of Health/National Institute of Neurological Disorders and Stroke Grants 1R01 NS 054193 and RO1 NS 42893 (to P.R.L.). The authors also acknowledge support from the Bram and Elaine Goldsmith and the Medallions Group Endowed Chairs in Gene Therapeutics (to P.R.L. and M.G.C., respectively). The Drown Foundation, the Linda Tallen & David Paul Kane Disorders and Stroke Grants 1RO1-NS 057711 and 1R21-NS054143 (to M.G.C.) and National Institutes of Health/National Institute of Neurological Disorders and Stroke Grants 1RO1 NS 054193 and RO1 NS 42893 (to P.R.L.). The authors also acknowledge support from The Bram and Elaine Goldsmith and the Medallions Group Endowed Chairs in Gene Therapeutics (to P.R.L. and M.G.C., respectively). The Drown Foundation, the Linda Tallen & David Paul Kane Disorders and Stroke Grants 1RO1-NS 057711 and 1R21-NS054143 (to M.G.C.) and National Institutes of Health/National Institute of Neurological Disorders and Stroke Grants 1R01 NS 054193 and RO1 NS 42893 (to P.R.L.).

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: pedrol@umich.edu

†a Current address: Laboratory for Regenerative and Protective Therapies of the Nervous System, Institute Leloir Foundation-IIBBA-National Council for Scientific and Technical Research, Buenos Aires, Argentina

‡b Current address: Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States of America

§c Current address: Departments of Neurosurgery, and Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, Michigan, United States of America

Introduction

Viruses cause infections in the brain that result in acute disease of varying severity associated with clearance of the virus, or in chronic progressive disease associated with virus persistence. CD8+ T cells are critical immune effectors for viral clearance [1,2] [3,4]; failure of CD8+ T cell effector function is associated with persistent infection of humans (i.e., HIV and hepatitis C virus), and mice (i.e., lymphocytic choriomeningitis virus) [5,6,7].

The functions of CD8+ T cells known to be important for virus clearance include their specificity for target antigens, cytotoxic activity and secretion of effector cytokines, and their capacity to migrate and localize to tissue sites of virus infection [8] [9]. In vivo, effector CD8+ T cells establish immunological synapses with target cells; immunological synapses constitute the anatomical substrate that facilitate the functional interactions of T cells with their specific targets [10,11,12,13,14,15,16,17]. Also, immunological synapses restrict the cytoxic effects of T cells exclusively to their targets; whether they also act similarly to restrict the effects and diffusion of effector cytokines remains unknown – there is evidence that many cytokines may either be secreted diffusely from T cells, or leak out of the immunological synapse – [18,19,20].

In some cases, viral infections in the brain could be limited by noncytolytic mechanisms such as IFN-γ [21]. Noncytolytic clearance of Sindbis virus has been described [22]. http://www.<plospathogens.org/article/findArticle.action?author = Burdeinick-
Kerr et al. indicated that noncytolytic 20% clearance of 20% Sindbis 20% virus 20% infection 20% from 20% neurons 20% gamma 20% interferon 20% dependent 20% an 20% Jak/STAT 20% signaling. To what degree different viruses are controlled in vivo through cytotoxic vs. non-cytolytic mechanisms remains to be determined.

Adenoviral vectors are powerful gene transfer tools for transgene expression in the brain. Adenoviral vectors transduce a variety of brain cells, including astrocytes, and allow long-term widespread transgene expression if injected directly and carefully into the brain parenchyma [23]. In the presence of an adenovirus immune response transgene expression and vector genomes are eliminated [17,23,24,25]. The immune response to viral vectors is an important challenge to gene therapy, as killing of transduced cells will counter therapeutic benefits.

Long term gene transfer in humans is limited by preexisting anti-adenoviral immunity, or when animals become immunized against adenovirus, as the adaptive immune response reduces transgene expression [17,23,26,27,28,29] [13]. In the context of this interaction IFN-γ becomes polarized at intercellular junctions between T cells and infected astrocytes [13].

Upon IFNγ release and binding to its receptor on target cells, IFNγ signals through the JAK-STAT pathway. This causes phosphorylation of STAT1; dimers of phosphorylated STAT1 translocate to the nucleus where, upon binding to specific IFNγ response elements (known as Gamma Activated Sites or GAS), they activate expression of a large number of IFNγ-inducible genes [30]. Subsequent expression of IFNγ-induced proteins is responsible for the antiviral effects of IFNγ.

To identify brain cells that have been exposed to IFNγ we developed a new detection system. Three adenoviral vectors containing the GAS element driving expression of the transgene Cre recombinase were produced. One vector did not contain any transgene in addition to the IFNγ-inducible Cre recombinase (Ad-GAS-Cre), a second one contained eGFP under the transcriptional control of a constitutive promoter (Ad-eGFP-GAS-Cre), and the third vector contained the HSV1-TK gene under the control of a constitutive MIE-hCMV promoter (Ad-TK-GAS-Cre). Cre recombinase was chosen as a transgene—the enzyme is identified by immunocytochemistry, as it becomes concentrated in the nucleus of target cells.

To determine the efficiency of our vectors to detect IFNγ release in the brain we injected the reporter adenoviral vectors into the brain, and at a later time, induced a systemic immune response to adenovirus, leading to the infiltration of the brain with antiviral CD8+ T cells, close interaction with the infected cells and predicted release of IFN-γ. As we detected expression of Cre recombinase, with all three vectors, we conclude that our vectors can be used as reporters to monitor the cellular targets of IFNγ secretion in the brain in vivo, during anti-viral immune responses.

Materials and Methods

Ethic statement

All animal work has been conducted according to relevant national and international guidelines. The work described was approved by the Institutional Animal Care and Use Committee at Cedars-Sinai Medical Center and conformed to the policies and procedures of the Cedars-Sinai Medical Center Comparative Medicine Department, and was approved under IACUC protocol number 2090.

Adenovirus vector constructions

Ad-GAS-Cre, Ad-eGFP-GAS-Cre, and Ad-TK-GAS-Cre are first-generation, replication defective serotype 5 adenovirus with deletions in the E1 and E3 regions. Ad-GAS-Cre is a novel vector constructed to detect IFNγ targeted cells. Ad-GAS-Cre encodes for Cre recombinase (a Type I topoisomerase from P1 bacteriophage) driven by an Interferon gamma activated sequence (GAS). Briefly, the GAS element was excised by BanIII digestion from pGAS-Luc (Strategene, La Jolla) and cloned into pSP72, generating pSP72-GAS-pA (3,362 bp). An extended version of Cre recombinase (nls Cre) encoding the nuclear localization signal (nls) from pSV40 large T antigen [31] was PCR amplified with specific primers designed introducing a TATA box in the 5’-extreme and flanking XbaI sites: Cre For 5’-GCTCTAGAGCT-TATATAATGGA-AAGGGAAGGAGTGGCCT-3’ and Cre Rev 5’-GCTCTAGAGCT-TATATAATGGA-AAGGGAAGGAGTGGCCT-3’; and then cloned into the XbaI site of pSP72-GAS-pA, generating pSP72-GAS-Cre (4,411 bp). The GASCre cassette was excised from pSP72-GAS-Cre by BglII digestion and ligated into pAE1sp1A (6,409 bp), generating pAE1sp1A-GAS-Cre (7,387 bp) [Figure 1A].

Figure S1.

Ad-hCMV.eGFP-GAS-Cre (Ad-eGFP-GAS-Cre) is a novel bicistronic adenovirus vector encoding: (i) enhanced green fluorescent protein (eGFP) gene driven by the human cytomegalovirus intermediate-early promoter (hCMV), (ii) GAS-Cre cassette. The pAE1sp1A-hCMV.eGFP plasmid was generated by cloning the hCMV.eGFP cassette from pAL119.eGFP into the BglII site of pAE1sp1A-GAS-Cre [Figure 1B].

Ad-hCMV.TK-GAS-Cre (Ad-TK-GAS-Cre) is a novel bicistronic adenovirus vector encoding: (i) HSV1 I Thymidine Kinase gene driven by the human cytomegalovirus intermediate-early promoter (hCMV), (ii) GAS-Cre cassette. The pAE1sp1A-hCMV.TK plasmid was generated by cloning the hCMV.TK cassette from pAL119.TK into the HindIII site of pAE1sp1A. The GAS-Cre cassette was excised from pSP72-GAS-Cre by BglII digestion and ligated into pAE1sp1A-hCMV.TK, generating pAE1sp1A-hCMV.TK-GAS-Cre (10,329 bp) [Figure 1C].

Ad-0, Ad-IFNγ, and Ad-HPRT have been described elsewhere [33]. First generation vectors were scaled up as described previously [33]. Vector preparations were screened for the presence of replication competent adenovirus and for lipopolysaccharide contamination (Cambrex, East Rutherford, NJ) [33]. Virus preparations used were free from replication competent adenovirus and lipopolysaccharide contamination.

Animals and surgical procedures

Female B6;129-Gt(RosA26)F3/J (ROSARo26) [Jackson Laboratories, Bar Harbor, ME) were injected into the right striatum as previously described with either 1 × 107 iu of Ad-GAS-Cre, Ad-TK-GAS-Cre, or Ad-eGFP-GAS-Cre. Two weeks later animals were injected systemically (intraperitoneal: ip) with either 5 × 109 iu of Ad-HPRT in 100 μl of solution or saline. Four weeks after systemic immunization with adenovirus, mice were anesthetized using ketamine (75 mg/kg) and dextrometomidine (0.5 mg/kg). At experimental endpoints mice were anesthetized and perfused-fixed and brains were processed for immunohistochemistry. Spleens were harvested during anesthesia, before perfusion, and processed for splenocyte isolation as described elsewhere [34]. Spleen cells were stored in liquid nitrogen until used.

C57/B6 mice (n = 2) were stereotactically injected bilaterally with 1 × 107 iu of Ad-eGFP-GAS-Cre and 21 days later with either Ad-0, Ad-IFNγ, or Ad-IFNγ (1 × 107 iu). Mice were euthanized 14 days later and brain sections were assessed by ICC for Cre recombinase. The numbers of Cre recombinase immunoreactive cells and eGFP expressing cells were quantified by stereology.
Immunohistochemistry and immunofluorescence

Coronal brain sections (50 μm thick) were used for immunohistochemistry to detect transgene expression or specific immune cells using methodologies described previously [33]. The primary antibodies used for immunohistochemical staining were the following: rabbit polyclonal anti-Cre recombinase (1:10,000) (Novagen), rabbit polyclonal anti-HSV1-TK (1:10,000) (produced by us) and rat anti-mouse CD8 \( \alpha \) (1:5,000) (Serotec, Raleigh, NC). Appropriate secondary antibodies were used: biotin-conjugated goat anti-rabbit immunoglobulin G (1:800), biotin-conjugated goat anti-rat immunoglobulin G (1:800) (DAKO, Glostrup, Denmark), Alexa 488-conjugated goat anti-rabbit (1:1,000), Alexa 594-conjugated goat anti-rat (1:1,000), Alexa 647-conjugated goat anti-rat (1:1,000) (Molecular Probes, Carlsbad, CA).

Quantification and stereological analysis

The number of labeled cells was quantified using a Zeiss AxioPlan 2 Imaging microscope (Carl Zeiss Microsystems, Thornwood, NY) controlled by a Ludl electronic MAC 5000 XY stage control (Ludl Electronics Products, Hawthorne, NY), and Stereo Investigator software [35]. Data was expressed as an absolute number of positive cells in each anatomical region analyzed. Results were expressed as the mean ± SEM.

Confocal imaging

Sections were examined using a Leica DMIRE2 confocal microscope (Leica Microsystems) and Confocal Software (Leica Microsystems), as described previously [16].
ELISPOT assay

As a measure of the cell-mediated immune response to adenovirus we assessed the frequency of IFN-γ-producing T cells using the ELISPOT kit assay (R&D Systems, Minneapolis, MN) according to the manufacturer’s instructions. Briefly, splenocytes (1 × 10^6 cells/well) were cultured in Millipore MultiScreen-HA plates (coated with anti-IFN-γ antibody) for 24 hours in X-Vivo media (Cambrex, Baltimore, MD) containing 1 × 10^5 iu/ml of heat-inactivated Ad-HPRT (inactivated at 85°C, for 15 minutes). The wells were then washed and incubated overnight at 4°C with biotinylated anti-IFN-γ detection antibodies (R&D Systems, Minneapolis, MN). Reactions were visualized using streptavidin-alkaline phosphatase, and 5-bromo-4-chloro-3-indolyphosphatase-p-toluidine salt, and nitro blue tetrazolium chloride as substrate [34]. The number of spots per 10^6 splenocytes, which represents the frequency of IFN-γ-producing cells, was counted with the KS ELISPOT automated image analysis system (Zeiss, Jena, Germany). Results were expressed as the mean ± SEM.

Depletion of circulating CD8+ T cells

To determine the optimum timing for the administration of CD8+ T cell depletion naive ROSA26 mice were injected i.p. with 0.5 mg of anti-CD8 depleting antibody once; 3, 7 and 8 days post-depletion two mice were euthanized for the identification of CD8+ T cells (CD3+ , CD4- , CD8+) by flow cytometry (Figure S4A). As the circulating levels of CD8+ T cells started to recover at 8 days post-injection of the depleting antibody, CD8-depleting antibodies were administered every 5 days, from 2 weeks post-systemic immunization (i.e., day 28, to euthanasia on day 42).

Statistical analysis

Data were analyzed by using a one way analysis of variance (ANOVA), followed by Tukey’s test, or paired T-test; results were expressed as the mean ± SEM. A ‘p’ value <0.05 was considered the cut off for significance.

Results and Discussion

Development of a novel system to detect IFNγ signaling in the brain in vivo

To identify and visualize IFN-γ secretion onto target cells during an active immune response against adenovirus, we generated three novel first generation adenoviral vectors encoding Cre recombinase under a promoter (GAS) that is inducible upon IFN-γ binding and stimulation of the IFN-γ receptor and its specific downstream signaling (Figures 1, 2). The schematic genetic structure of all three vectors, Ad-GAS-Cre, Ad-TK-GAS-Cre, or Ad-eGFP-GAS-Cre, is shown in Figure 1.

Ad-GAS-Cre was constructed first; upon stimulation with IFNγ Cre recombinase expression was detected demonstrating the functionality of the GAS-Cre IFNγ inducible expression cassette within first generation adenoviral vectors. However, Ad-GAS-Cre does not allow to detect transduction of target cells in the absence of IFNγ. Thus, to identify transduced cells during an anti-adenoviral immune response, and to be able to do so independently of the presence of IFNγ we constructed two additional vectors, Ad-eGFP-GAS-Cre (Figure 1B), and Ad-TK-GAS-Cre (Figure 1C). Ad-EGFP-Cre encodes the fluorescent protein enhanced green fluorescent protein, and Ad-TK-GAS-Cre the HSV-1 Thymidine Kinase; expression of eGFP and HSV1-TK are under the control of a constitutive promoter. Vector-mediated detection of IFNγ signaling in target cells is illustrated in Figure 2.

Transient expression of Cre recombinase at early time points after first generation adenoviral vectors administration

To determine the existence of any basal expression from our vectors in the absence of a systemic immune response C57/B6 mice were intracranially injected with all three viruses. At 3 days after injection we detected Cre recombinase expression from all vectors (Figure 3A). To determine whether early Cre recombinase expression is stable or transient C57/B6 mice were stereotactically injected bilaterally in the brain striatum with Ad-eGFP-GAS-Cre and euthanized 3, 7, 14, 21, 28, and 60 days after injection. Quantification of eGFP expression, an indication of adenovirus transduction, was stable over 60 days (Figure 3B). Importantly, expression of Cre recombinase was reduced over time (Figure 3C), indicating that the early expression is transient. As Cre recombinase expression reached basal levels at 14 days post-injection, and remained low until 60 days post-injection, it was decided that in experiments to test the effect of a systemic immune response, animals would be immunized at 14 days post-delivery of vectors into the brain, and then sacrificed at either 2 or 4 weeks later to determine whether the systemic immune response was able to induce Cre recombinase expression. Administration of systemic IFNγ or IFNγ through adenoviral vectors did not increase Cre recombinase expression in the brain (data not shown).

Cre recombinase is expressed in the brains of mice during an adenovirus specific systemic immune response

ROS26 mice were injected into the right striatum with 1 × 10^7 iu of Ad-Gas.Cre (Figure 4). Two weeks later animals...
were injected ip with either $5 \times 10^8$ iu of Ad-HPRT or saline. Two or four weeks after systemic immunization with adenovirus, mice were euthanized, perfused fixed, and 50 µm thick brain sections were analyzed for expression of Cre recombinase. To confirm the efficacy of the immunization, total splenocytes were analyzed for the frequency of IFNγ-secreting immune cells by IFNγ ELISPOT in response to stimulation with adenovirus (Figure 4F). At 2 and 4 weeks post immunization the levels of Cre recombinase expression in the brain were elevated (Figure 4G, D, E). There was no difference in the increase of Cre recombinase expression between males and females (Figure 4E). These data suggest that IFNγ release in the brain following systemic immunization against adenovirus, mediates an increase in the expression of Cre recombinase. ROSA26 mice were utilized to determine whether Cre recombinase expression would remove the STOP sequence within the endogenous ROSA26 locus and activate expression of the enzyme β-galactosidase. However, we never were able to detect expression of β-galactosidase. This suggests that either the
GAS element alone does not produce sufficient levels of Cre recombinase expression to achieve the excision of the STOP sequence, or that the target cells' physiology is affected by the immune system, in such a way that proper gene expression becomes impaired.

Ad-eGFP-GAS-Cre as a tool to visualize the interactions between CD8$^+$ T cells and target brain cells

Ad-eGFP-GAS-Cre (1 x 10$^7$ iu) was injected into the right striatum of ROSA26 mice (Figure 5). Two weeks later animals were injected systemically with either 5 x 10$^7$ iu of Ad-HPRT or saline. Four weeks after systemic immunization with Ad-HPRT, mice were euthanized and brain sections were analyzed for the expression of Cre recombinase and CD8$^+$ T cells, and among CD8$^+$ T and brain cells expressing Cre recombinase, were detected in immunized animals (Figure 5A). No CD8$^+$ T cells, or Cre recombinase expression were detected in saline immunized animals (data not shown). As morphological changes were detected in infected cells, which were attributed to eGFP, we sought to study the detailed responses to systemic immunization utilizing a different transgene, namely HSV1-TK.

**Figure 4.** Systemic immunization against adenovirus induces Cre recombinase expression in mice injected with Ad-GAS-Cre. A. ROSA26 mice (n = 5) were stereotactically injected in the striatum with Ad-GAS-Cre, immunized i.p. 14 days later mice with Ad-HPRT or saline; and euthanized 2 or 4 weeks after immunization; brain sections were assessed by ICC for Cre recombinase. B. Diagram depicting the paradigm for the IFN$\gamma$ inducible phenotype of Ad-GAS-Cre infected brain cells in our model; i.e., systemic immunization causes nuclear localization of the transgene Cre recombinase (illustrated as black nuclei upon availability of IFN$\gamma$). C. Cre recombinase immunoreactivity is increased in striatal cells at 2 and 4 weeks post-systemic anti-adenoviral immunization; *, p<0.05 versus saline, by paired T-test. D. Representative micrographs illustrate striatal cells expressing nuclear Cre recombinase at 2 weeks or 4 weeks post-immunization; E. When discriminated by sex, no significant differences were found in the number of Cre recombinase expressing cells in the brain of males compared to females in either sham or immunized mice; *, p<0.05 versus saline, by paired T-test. F. Total splenocytes were tested to determine the frequency of IFN$\gamma$ secreting lymphocytes specific for adenovirus antigens using ELISPOT assay. Concanavalin A (ConA) was used as a control mitogen. *, p<0.05 versus saline, by paired T-test.

doi:10.1371/journal.pone.0023523.g004
**IFNγ** signaling is increased during the elimination of virally infected cells in the brain following the systemic immunization against adenovirus

ROSA26 mice were stereotactically injected in the brain with Ad-TK-GAS-Cre, immunized 2 weeks later with Ad-HPRT or saline, and euthanized 4 weeks post-immunization; brain sections were assessed by ICC for Cre recombinase and CD8+ T cells (CD3+CD8+). Increased frequency of IFNγ secreting lymphocytes specific for adenovirus antigens, and detected using an ELISPOT assay, was detected among total splenocytes (**Figure 6C**). Our results show that the systemic adenovirus immune response induces abundant CD8+ T cell infiltration of the brain, and an increase in the expression of Cre recombinase from an IFNγ sensitive promoter, suggesting the presence of elevated IFNγ signaling during the loss of HSV1-TK expression.

**CD8+ T cells are necessary for induction of IFNγ-inducible Cre recombinase expression in vivo**, during the loss HSV1-TK expression from adenoviral vectors

To determine the role of CD8+ T cells in stimulating IFNγ-inducible Cre recombinase during a systemic anti-adenoviral immune response, we depleted CD8+ T cells from animals that were systemically immunized against adenovirus; CD8+ T cell was achieved using a specific depleting antibody (set up experiment is illustrated in **Figure 4A**). ROSA26 mice were stereotactically injected in the brain with Ad-TK-GAS-Cre, 2 weeks later immunized ip with Ad-HPRT. One group of animals was then injected ip injection of anti-CD8 depleting antibody (or isotype control) two weeks post-immunization, and followed with additional injections of depleting antibodies every 5 days until euthanasia (**Figure 7A**). Brain sections were analyzed for the expression of Cre recombinase and HSV1-TK. The number of HSV1-TK expressing cells decreased significantly in immunized animals treated either with no antibodies, or isotype control, while no decrease was observed in animals treated with the anti-CD8 depleting antibody (**Figure 7B**). Flow cytometry analysis revealed effective reduction of CD8+ T cells (CD3+CD4−CD8+) in the spleens of mice after treatment with anti-CD8 depleting antibody; and no difference was detected between groups of animals which had been immunized and either treated with isotype control antibody or none (**Figure 7C**). We also determined the number of neurons in which we could still detect HSV1-TK, but were otherwise atrophied, as they were devoid of normal cellular processes shown by cells in non-immunized animals (**Figure 7D**); in parallel, the number of Cre recombinase expressing cells increased in immunized animals that were injected with either isotype antibody or no antibody, but increased much less in immunized animals depleted of CD8+ T cells (**Figure 7E**). These results suggest that IFNγ induces expression of Cre recombinase and that this nuclear expression remains detectable in cells otherwise undergoing atrophy in response to the immune attack, and that CD8+ T cells are the main producers of IFNγ in the brain during the antiviral immune response, and thus, directly responsible for the activation of Cre recombinase in target cells.

**Conclusions**

In order to fully understand the cellular and molecular dynamics of the brain immune response, it is important to be able to determine which target cells are influenced during the brain infiltration with CD8+ T cells, as these aim to clear the brain from virally infected cells. To determine which cells in the brain respond to IFNγ secreted from T cells upon activation, we developed a series of viral vectors encoding an IFNγ responding element. Using these vectors we demonstrate that widespread IFNγ signaling does indeed occur, as it can be effectively detected in a large amount of target cells during immune-mediated...
elimination of adenovirally infected cells. The presence of large numbers of Cre recombinase expressing cells during the peak of the brain infiltration with anti-viral T cells suggests a large amount of IFNγ activity. The atrophic nature of remaining cells expressing Cre recombinase and HSV1-TK, together with their inability of expressing β-galactosidase, suggests that brain cells targeted by the

Figure 6. Systemic immunization against adenovirus induces Cre recombinase expression in brain cells infected with Ad-TK-GAS-Cre. A. ROSA26 mice (n = 5) were stereotactically injected in the brain with Ad-TK-GAS-Cre, immunized i.p. 14 days later with Ad-HPRT or saline, and euthanized 4 weeks after immunization. B. Diagram depicting the paradigm for the IFNγ inducible phenotype of Ad-TK-GAS-Cre infected brain cells in our model; i.e., systemic immunization causes nuclear localization of the transgene Cre recombinase (illustrated as dark nuclei upon availability of IFNγ, within grey cells expressing HSV1-TK). C. HSV1-TK immunoreactivity was used to quantitate levels of viral transduction in the brain, and illustrates the decrease in HSV1-TK transgene expression upon immunization. D. Cre recombinase immunoreactivity was used to quantitate the level of IFNγ dependent signaling during the anti-adenoviral systemic immune response. E. Micrographs depict cells expressing HSV1-TK (left panel), CD8⁺ T cells (middle panel), and Cre recombinase (right panel) staining in representative striatal sections from saline treated or mice immunized with Ad-HPRT. F. Total splenocytes were assessed for the frequency of IFNγ secreting lymphocytes specific for adenovirus antigens using ELISPOT assay. Concanavalin A (ConA) was used as a control mitogen. *, p<0.05 versus saline, by paired T-test.

doi:10.1371/journal.pone.0023523.g006
immune system remain with a highly compromised viability. Together with many other data demonstrating the loss of transduced cells in this and similar paradigms, suggests that the immune response is able to eliminate transduced cells from the brain, or seriously damage their physiology. Our data demonstrate that IFNγ signaling occurs in target cells during the brain antiviral immune response. Our novel method could be used further to study the in vivo dynamics of IFNγ secretion and signaling onto...
target cells in a number of experimental paradigms of neuroimmune pathology.

**Supporting Information**

**Figure S1** Cloning strategy illustrating the molecular construction of pΔE1sp1A-GAS-Cre. (i) Luc gene was cut from pGAS-Luc with XbaI, then pGAS was cut with BamHI and cloned into the BglII site of pSP72BglII to make pSP72-GAS-PolyA; (ii) nlsCre was cut from pGemTATACre with XbaI and cloned into the XbaI site of pSP72-GAS-PolyA to make pSP72-GAS-Cre; (iii) GAS-Cre cassette was cut from pSP72-GAS-Cre with BglII and cloned into the BglII site of pΔE1sp1A to make pΔE1sp1A-GAS-Cre, which was used to construct Ad-TK-GAS-Cre. (TIF)

**Figure S2** Cloning strategy illustrating the molecular development of pΔE1sp1A-hCMVEGFP-GAS-Cre adenovirus genome plasmids. (i) The hCMV eGFP polyA cassette was excised from pAL119GFP (8,178 bp) by HindIII digestion, extremes were blunted and cloned into EcoRV site of pΔE1sp1A, generating pΔE1sp1A-hCMV.eGFP (7,923 bp). (ii) The GAS-Cre-polyA cassette from pSP72-GAS-polyA (3,374 bp) was excised with BglII and cloned into the BglII site of pΔE1sp1A-hCMV.eGFP, generating pΔE1sp1A-hCMV.eGFP-GAS-nlsCre (9,969 bp), which was used to construct Ad-eGFP-Cre. (TIF)

**References**

1. Topham DJ, Tripp RA, Doherty PC (1997) CD8+ T cells clear influenza virus by perforin or Fas-dependent processes. J Immunol 159: 5197–5200.
2. Lehmann-Gruhe F, Krenz I, Krahner T, Schwacheneder R, Moskophidis D, et al. (1987) Mechanism of recovery from acute virus infection. IV. Questionable role of mononuclear phagocytes in the clearance of lymphocytic choriomeningitis virus from spleens of mice. J Immunol 138: 2282–2289.
3. Stevenson PG, Hawke S, Sloan DJ, Bangham CR (1997) The immunogenicity of intracranial virus infection depends on anatomical site. J Virol 71: 145–151.
4. Lowenstein PR (2002) Immunology of viral-vector-mediated gene transfer into the brain: an evolutionary and developmental perspective. Trends Immunol 23: 21–30.
5. Zajac AJ, Blattman JN, Murali-Krishna K, Sourdive DJ, Suresh M, et al. (1998) CD8+ T cells are required for clearance of virally infected brain cells. J Immunol 160: 2305–2313.
6. Wolff M, Rutebemberwa A, Mosbruger T, Mao Q, Li HM, et al. (2008) Hepatitis C virus immune activation leads to occult infection of a hole in the T cell repertoire. J Immunol, United States. pp 6435–6446.
7. Rutebemberwa A, Ray SC, Astemborski J, Levine J, Liu L, et al. (2008) High-programmed death-1 levels on hepatitis C virus-specific T cells during acute infection are associated with viral persistence and require preservation of cognate antigen during chronic infection. J Immunol, United States. pp 8215–8225.
8. Bennet MS, Ng HL, Dagarag M, Ali A, Yang OO (2007) Epitope-dependent avidity thresholds for cytotoxic T-lymphocyte clearance of virus-infected cells. J Virol, United States. pp 4973–4980.
9. Ransohoff RM, Kivisakk P, Kidd G (2003) Three or more routes for leukocyte migration into the central nervous system. Nat Rev Immunol, London. pp 247–255.
10. Nishikawa ZM, Oelke M, Schneck JP, Griffin DE (2010) Dynamic regulation of functionally distinct virus-specific T cells. Proc Natl Acad Sci U S A, United States. pp 3669–3674.
11. Stinchcombe JC, Salio M, Cerundolo V, Peede D, Arico M, et al. (2011) Centrocentric polarization to the immunological synapse directs secretion from cytolytic cells of both the innate and adaptive immune systems. BMC Biol. 45 p.
12. Dustin ML, Long EO (2010) Cytotoxic immunological synapses. Immunol Rev, Denmark. pp 24–54.
13. Barcia C, Wyszowsky K, Barrett RJ, Liu C, Castro MG, et al. (2008) In vivo polarization of IFN-gamma at Kupfer and non-Kupfer immunological synapses during the clearance of virally infected brain cells. J Immunol 180: 1344–1352.
14. Haiman E, Burack WR, Shaw AS, Dustin ML, Allen PM (2002) Immature CD4+CD8+ thymocytes form a multifocal immunological synapse with sustained tyrosine phosphorylation. Immunity, United States. pp 839–848.
15. Jenkins MR, Tsau A, Stinchcombe JC, Griffiths GM (2009) The strength of T cell receptor signal controls the polarization of cytotoxic machinery to the immunological synapse. Immunity, United States. pp 621–631.
16. Barcia C, Sanderson NS, Barrett RJ, Wasywosky K, Kroeger KM, et al. (2008) T cells' immunological synapses induce polarization of brain astrocytes in vivo and in vitro. A novel astrocyte response mechanism to cellular injury. PLoS ONE 3: e9277.
17. Barcia C, Thomas CE, Carmin JF, King GD, Wasywosky K, et al. (2006) In vivo mature immunological synapses forming SMAG's mediate clearane of virally infected astrocytes from the brain. J Exp Med 203: 2095–2107.
18. Sanderson N, Puntel M, Kroeger KM, Bondale N, Iranmanesh N, et al. (2011) Immunological synapses do not restrict secretion of interferon-gammar (gamma) during antigen-specific lysis of target cells by CD8+ cytotoxic T lymphocytes. The Journal of Immunology 186: 8012.
19. Huse M, Lillemeier BF, Kuhnis MS, Chen DS, Davis MM (2006) T cells use two directionally distinct pathways for cytokine secretion. Nat Immunol, United States. pp 527–535.
20. Huse M, Quan SJ, Davis MM (2008) Shouts, whispers and the kiss of death: directional secretion in T cells. Nat Immunol, United States. pp 1105–1111.
21. Griffin DE (2011) Viral encephalomyelitis. PLoS Pathog 7: e1002004.
22. Burdineck-Kerr R, Govindarajan D, Griffin DE (2009) Noncytolytic clearance of adrenal virus infection from neurons by gamma interferon is dependent on Jak/STAT signaling. J Virol, United States. pp 3439–3455.
23. Barcia C, Jimenez-Dalmaroni M, Kroeger KM, Puntel M, Rapaport AJ, et al. (2007) Sustained one expression from high-capacity helper-dependent adenovirus vectors delivered to the brain of animals with a pre-existing systemic antadenoviral immune response: implications for clinical trials. Med Ther 15: 2134–2163.
24. Thomas CE, Schiedner G, Kocahan S, Castro MG, Lowenstein PR (2000) Peripherial infection with adenovirus causes unexpected long-term inflammation in animals injected intracranially with first-generation, but not with high-capacity, adenovirus vectors: toward realistic long-term neurological gene therapy for chronic diseases. Proc Natl Acad Sci U S A 97: 7482–7487.
25. Zirger JM, Puntel M, Bergeron M, Wibowo M, Bondale M, et al. (2011) Immuno-mediated loss of transgene expression from virally-transduced brain cells is irreversible, mediated by IFNγ, IFNα, and in vivo: a novel astrocyte response mechanism to cellular injury. PLoS ONE 3: e2977.
26. Thomas CE, Schiedner G, Kocahan S, Castro MG, Lowenstein PR (2001) Preexisting antadenoviral immunity is not a barrier to efficient and stable transduction of the brain, mediated by novel high-capacity adenovirus vectors. Hum Gene Ther 12: 839–846.
27. Byrne AP, Rusby JE, Wood MJ, Charlton HM (1995) Adenovirus gene transfer causes inflammation in the brain. Neuroscience 66: 1015–1024.
28. Byrne AP, MacLaren RE, Charlton HM (1996) Immunological instability of persistent adenovirus vectors in the brain: peripheral exposure to vector leads to renewed inflammation, reduced gene expression, and demyelination. J Neurosci 16: 3045–3055.
29. Byrne AP, Wood MJ, Charlton HM (1996) Role of T cells in inflammation caused by adenovirus vectors in the brain. Gene Ther 3: 644–651.
30. Kim TK, Maniatis T (1996) Regulation of interferon-gamma-activated STAT1 by the ubiquitin-proteasome pathway. Science 273: 1717–1719.
31. Kanegae Y, Lee G, Sato Y, Tanaka M, Nakai M, et al. (1995) Efficient gene activation in mammalian cells by using recombinant adenovirus expressing site-specific Cre recombinase. Nucleic Acids Res 23: 3816–3821.
32. Gattaceca F, Pilatte Y, Billard C, Monnet I, Moritz S, et al. (2002) Ad-IFN gamma induces antiproliferative and antitumoral responses in malignant mesothelioma. Clin Cancer Res 8: 3298–3304.
33. Southgate T, Kroeger KM, Liu C, Lowenstein PR, Castro MG (2008) Gene transfer into neural cells in vitro using adenoviral vectors. Curr Protoc Neurosci. ChichesterNew York: John Wiley & Sons, Inc. pp 4.23.21–24.23.43.
34. Puntel M, Kroeger KM, Sanderson NS, Thomas CE, Castro MG, et al. (2010) Gene transfer into rat brain using adenoviral vectors. Curr Protoc Neurosci Chapter 4: Unit 4 24.
35. Suwelack D, Hurtado-Lorenzo A, Millan E, Gonzalez-Nicolini V, Wawrowsky K, et al. (2004) Neuronal expression of the transcription factor Gli1 using the Talphat1 alpha-tubulin promoter is neuroprotective in an experimental model of Parkinson’s disease. Gene Ther 11: 1742–1752.